BioAge Competitors
| BIOA Stock | 18.99 0.11 0.58% |
BioAge Labs vs Humacyte Correlation
Excellent diversification
The correlation between BioAge Labs and HUMA is -0.67 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding BioAge Labs and HUMA in the same portfolio, assuming nothing else is changed.
Moving together with BioAge Stock
| 0.86 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.82 | MRK | Merck Company Earnings Call Tomorrow | PairCorr |
| 0.84 | AARD | Aardvark Therapeutics | PairCorr |
Moving against BioAge Stock
| 0.87 | JUNS | Jupiter Neurosciences | PairCorr |
| 0.87 | PBCRY | Bank Central Asia | PairCorr |
| 0.5 | PBCRF | PT Bank Central | PairCorr |
| 0.47 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.41 | MMM | 3M Company | PairCorr |
BioAge Labs Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BioAge Labs and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of BioAge and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BioAge Labs does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between BioAge Stock performing well and BioAge Labs Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BioAge Labs' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| LFCR | 2.12 | 0.37 | 0.17 | 0.29 | 2.03 | 6.17 | 15.24 | |||
| CGC | 4.55 | (0.03) | 0.00 | (0.05) | 0.00 | 8.55 | 66.41 | |||
| ALLO | 4.05 | 0.68 | 0.15 | 0.46 | 3.83 | 12.38 | 26.97 | |||
| EDIT | 3.10 | (0.72) | 0.00 | (0.37) | 0.00 | 6.56 | 21.57 | |||
| TKNO | 3.01 | (1.19) | 0.00 | (0.93) | 0.00 | 4.75 | 19.09 | |||
| ACB | 2.42 | (0.30) | 0.00 | (0.93) | 0.00 | 3.56 | 26.49 | |||
| AVIR | 2.26 | 0.42 | 0.12 | 0.60 | 3.02 | 5.54 | 17.79 | |||
| OMI | 3.88 | (0.85) | 0.00 | 2.12 | 0.00 | 6.88 | 27.99 | |||
| CABA | 4.83 | 0.12 | 0.02 | 0.14 | 4.96 | 8.44 | 62.77 | |||
| HUMA | 3.72 | (0.76) | 0.00 | (0.30) | 0.00 | 8.16 | 20.54 |
Cross Equities Net Income Analysis
Compare BioAge Labs and related stocks such as Lifecore Biomedical, Canopy Growth Corp, and Allogene Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LFCR | (4.2 M) | 12.7 M | 22.6 M | 19.1 M | 13.5 M | (11.6 M) | 10.6 M | 24.8 M | 2.1 M | (38.2 M) | (32.3 M) | (97.4 M) | (116.7 M) | 12 M | (38.7 M) | (34.8 M) | (33.1 M) |
| CGC | (26.9 K) | (21.4 K) | (64.6 K) | (932.9 K) | (8.9 M) | (3.5 M) | (16.6 M) | (54.1 M) | (670.1 M) | (1.3 B) | (1.7 B) | (310 M) | (3.3 B) | (657.3 M) | (598.1 M) | (8.9 M) | (9.4 M) |
| ALLO | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (211.5 M) | (184.6 M) | (233.5 M) | (244.8 M) | (329.8 M) | (327.3 M) | (257.6 M) | (231.8 M) | (243.4 M) |
| EDIT | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (13.7 M) | (72.9 M) | (97.2 M) | (120.3 M) | (110 M) | (133.7 M) | (109.4 M) | (185.1 M) | (204.4 M) | (153.2 M) | (237.1 M) | (213.4 M) | (202.7 M) |
| TKNO | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | 3.6 M | (9.8 M) | (47.5 M) | (36.8 M) | (26.7 M) | (24.1 M) | (25.3 M) |
| ACB | 1.3 K | (315.8 K) | (393.5 K) | (399.7 K) | (9.5 M) | (5.7 M) | (13 M) | 71.9 M | (293.5 M) | (3.3 B) | (693.6 M) | (1.7 B) | (816.6 M) | (69.3 M) | 1.6 M | 1.4 M | 1.5 M |
| AVIR | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (9.1 M) | (13.5 M) | (10.9 M) | 121.2 M | (115.9 M) | (136 M) | (168.4 M) | (151.5 M) | (144 M) |
| CABA | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (250 K) | (12.2 M) | (15.1 M) | (32.5 M) | (45.5 M) | (51.8 M) | (67.7 M) | (115.9 M) | (104.3 M) | (99.1 M) |
| HUMA | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (85.4 M) | (66.5 M) | (26.5 M) | (12 M) | (110.8 M) | (148.7 M) | (133.8 M) | (127.1 M) |
BioAge Labs and related stocks such as Lifecore Biomedical, Canopy Growth Corp, and Allogene Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in BioAge Labs financial statement analysis. It represents the amount of money remaining after all of BioAge Labs operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.BioAge Labs Competitive Analysis
The better you understand BioAge Labs competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BioAge Labs' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BioAge Labs' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
BioAge Labs Competition Performance Charts
Five steps to successful analysis of BioAge Labs Competition
BioAge Labs' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BioAge Labs in relation to its competition. BioAge Labs' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of BioAge Labs in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BioAge Labs' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BioAge Labs, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your BioAge Labs position
In addition to having BioAge Labs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hedge Favorites Thematic Idea Now
Hedge Favorites
Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. The Hedge Favorites theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hedge Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BioAge Labs Correlation with its peers. For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs. Projected growth potential of BioAge fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive BioAge Labs assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate BioAge Labs using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating BioAge Labs' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause BioAge Labs' market price to deviate significantly from intrinsic value.
It's important to distinguish between BioAge Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAge Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, BioAge Labs' market price signifies the transaction level at which participants voluntarily complete trades.